OnKure Therapeutics, Inc.
OKURHealthcare|Biotechnology|US
$2.87
+0.34 (+13.47%)
DCF Value
$4.23
Tangible Book / Share
$3.16
Cash / Share
$3.27
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06239467 First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | Advanced Cancer, Breast Cancer | P1 | Active | 200 | RCT, Open-label | OKI-219, Fulvestrant, Trastuzumab, Tucatinib, Atirmociclib, Ribociclib |
| NCT05267574 An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) | Primary Mitochondrial Myopathy | P2P3 | Terminated | 155 | Open-label | REN001 |
| NCT05340621 NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | RAS Mutation, NRAS Gene Mutation | P1P2 | Completed | 36 | Open-label | OKI-179 + binimetinib |
| NCT04535609 An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients | Primary Mitochondrial Myopathy | P2 | Completed | 213 | RCT, Double-blind | Mavodelpar, Placebo |
| NCT04226274 A Study of the Safety of REN001 in Patients With McArdle Disease | McArdle Disease | P1 | Completed | 19 | Open-label | REN001 |
| NCT03931681 A Study of OKI-179 in Patients With Solid Tumors | Advanced Solid Tumors | P1 | Completed | 34 | Open-label | OKI-179 |
| NCT03862846 A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy | Primary Mitochondrial Myopathy | P1 | Terminated | 23 | Open-label | REN001 |
| NCT03833128 A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders | Fatty Acid Oxidation Disorders | P1 | Completed | 24 | Open-label | Low Dose REN001, High Dose REN001 |
| NCT04482049 A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders | Fatty Acid Oxidation Disorder | Completed | 61 | — | — |